AI Summary
We reviewed 88 live results for actemra intravenous (iv) infusion and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biologics and Immunosuppressants.
Comparison Table
Recommended
Actemra Intravenous (IV) Infusion
Source: Roche
Description
Actemra is an Interleukin-6 (IL-6) receptor antagonist containing the active ingredient tocilizumab. This intravenous formulation is used for treating moderate to severe active Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). In Thailand, it is available in 80 mg, 200 mg, and 400 mg vials (20 mg/mL), distributed through DKSH. It is a critical biologic therapy for controlling systemic inflammation and joint damage.
Best for
Rheumatoid arthritis management, Juvenile idiopathic arthritis, Hospital-based IV treatment and Thai local access
View Details
Rating
Truxima Intravenous Infusion Administration
Source: Hospital Kuala Lumpur
Description
Clinical administration of Truxima (rituximab biosimilar) for the treatment of hematological cancers and autoimmune disorders, provided within a supervised hospital setting with specialized oncology support.
Best for
Public healthcare patients, Hematological malignancy treatment, Supervised IV infusion and Oncology care in Kuala Lumpur
View Details
Rating
Outpatient Intravenous Immunoglobulin (IVIg) Infusion
Source: National University Hospital (NUH)
Description
The Outpatient Parenteral Infusion Clinic (OPIC) at NUH provides administration of IVIg and blood products. This service is designed for stable patients with immunodeficiency, autoimmune, or neurological disorders who require regular immunoglobulin therapy in a clinical outpatient setting.
Best for
patients with chronic immunodeficiency, autoimmune disorder management, neurological treatment and outpatient medical care
View Details
Rating
| Compare | Actemra Intravenous (IV) Infusion | Truxima Intravenous Infusion Administration | Outpatient Intravenous Immunoglobulin (IVIg) Infusion |
|---|---|---|---|
| Source | Roche | Hospital Kuala Lumpur | National University Hospital (NUH) |
| Description | Actemra is an Interleukin-6 (IL-6) receptor antagonist containing the active ingredient tocilizumab. This intravenous formulation is used for treating moderate to severe active Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). In Thailand, it is available in 80 mg, 200 mg, and 400 mg vials (20 mg/mL), distributed through DKSH. It is a critical biologic therapy for controlling systemic inflammation and joint damage. | Clinical administration of Truxima (rituximab biosimilar) for the treatment of hematological cancers and autoimmune disorders, provided within a supervised hospital setting with specialized oncology support. | The Outpatient Parenteral Infusion Clinic (OPIC) at NUH provides administration of IVIg and blood products. This service is designed for stable patients with immunodeficiency, autoimmune, or neurological disorders who require regular immunoglobulin therapy in a clinical outpatient setting. |
| Best for | Rheumatoid arthritis management, Juvenile idiopathic arthritis, Hospital-based IV treatment and Thai local access | Public healthcare patients, Hematological malignancy treatment, Supervised IV infusion and Oncology care in Kuala Lumpur | patients with chronic immunodeficiency, autoimmune disorder management, neurological treatment and outpatient medical care |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Actemra Intravenous (IV) Infusion from Roche."
I picked this because This is the primary originator brand registered and commercially available in Thailand, with established government reference pricing and local distribution.
Share this search
Related Finds